All News

14 February 2025

Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo NodularisAntibodies

14 February 2025

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid GelsProteins and Peptides

14 February 2025

European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 VaccineVaccines

14 February 2025

Kexing Biopharm Obtained IND Approval for Its Self-developed GB05 from U.S. FDAProteins and Peptides

14 February 2025

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025Antibodies

14 February 2025

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 TrialAntibodies

13 February 2025

Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate CancerSmall Molecules

13 February 2025

Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101Small Molecules

13 February 2025

European Commission Approves CSL’s ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)Antibodies

13 February 2025

FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)Small Molecules

13 February 2025

U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaAntibodies

13 February 2025

Study Results Abstracts From Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) At 2025 ASCO Genitourinary Cancers SymposiumAntibodies

13 February 2025

Restore Vision Announces First Patient Dosed in Phase I/II Clinical Trial of RV-001 for Gene-Agnostic Retinitis PigmentosaDNA RNA and Cells

13 February 2025

Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical studyVaccines

12 February 2025

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 MonthsAntibodies

12 February 2025

Xilio Therapeutics Announces Multiple Masked T Cell Engager ProgramsAntibodies

12 February 2025

Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body MyositisAntibodies

12 February 2025

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated ImmunotherapiesAntibodies

12 February 2025

GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT StudyDNA RNA and Cells

12 February 2025

Ellipses In-Licences First in Class Novel Immuno-Oncology Agent With Potential as a Next Generation Checkpoint InhibitorAntibodies

12 February 2025

Lineage Initiates Clinical Study of OPC1 for Spinal Cord InjuryDNA RNA and Cells

12 February 2025

Alloy Therapeutics Establishes Multi-Year Collaboration with Pfizer to Develop New Antibody Discovery PlatformMore News

12 February 2025

U.S. FDA approves Celltrion’s AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA®Antibodies

12 February 2025

Lion TCR’s Liocyx-M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV-Related Hepatocellular CarcinomaDNA RNA and Cells

12 February 2025

Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple MyelomaAntibodies

12 February 2025

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CMSmall Molecules

11 February 2025

Rondo Therapeutics Presents Preclinical Data at ASCO GU for its Novel CD28 x Nectin-4 Costimulatory Bispecific Antibody for Advanced Bladder CancerAntibodies

11 February 2025

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)Antibodies

11 February 2025

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfrontAntibodies

11 February 2025

The first patient has been dosed in a phase 2 clinical study of HLX43 for injection (antibody-drug conjugate targeting PD-L1 with novel DNA topoisomerase I inhibitor) for the treatment of recurrent/metastatic esophageal squamous cell carcinoma (ESCC)Antibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

CD73 Inhibitor Pipeline Review

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Her3-Targeted Immunotherapy Pipeline Review

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

Adalimumab (Humira) Biosimilars Pipeline Review

CD40 Agonists & CD40/L Antagonists Pipeline Review

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Bispecific Antibodies for Immuno-Oncology & Other Diseases